AR079059A1 - Acido ((3s)-3-(((1-(((2r)-2-carboxi-4-(1-naftil) butil) ciclopentil)-carbonil) amino )-2-oxo-2,3,4,5-tetrahidro-1h-1-benzazepin-1-il) acetico cristalino, su preparacion y uso - Google Patents

Acido ((3s)-3-(((1-(((2r)-2-carboxi-4-(1-naftil) butil) ciclopentil)-carbonil) amino )-2-oxo-2,3,4,5-tetrahidro-1h-1-benzazepin-1-il) acetico cristalino, su preparacion y uso

Info

Publication number
AR079059A1
AR079059A1 ARP100104251A ARP100104251A AR079059A1 AR 079059 A1 AR079059 A1 AR 079059A1 AR P100104251 A ARP100104251 A AR P100104251A AR P100104251 A ARP100104251 A AR P100104251A AR 079059 A1 AR079059 A1 AR 079059A1
Authority
AR
Argentina
Prior art keywords
benzazepin
oxo
carbonyl
amino
acid
Prior art date
Application number
ARP100104251A
Other languages
English (en)
Inventor
Rheenen Jeroen Van
Dasselaar Eric Eibert Van
Guido Dirk Batema
Jong Paulus Petrus Gerardus De
Touria Elhamdaoui-Achterberg
Nicolaas Buizer
Gerrit Klein
Original Assignee
Abbott Healthcare Products Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Healthcare Products Bv filed Critical Abbott Healthcare Products Bv
Publication of AR079059A1 publication Critical patent/AR079059A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16—Benzazepines; Hydrogenated benzazepines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Composicion farmacéutica y proceso de preparacion. Reivindicacion 1: Ácido {(3S)-3-[((1-[(2R)-2-carboxi-4-(1-naftil)butil]ciclopentil}-carbonil)amino]-2-oxo-2,3,4,5-tetrahidro-1H-1-benzazepin-1-il)acético cristalino, caracterizado porque es el compuesto de formula (1). Reivindicacion 2: El compuesto de acuerdo con la reivindicacion 1, caracterizado porque tiene un espectro de difraccion de rayos X de polvo que tiene reflejos característicos (expresados en grados del ángulo de difraccion 2 theta) a: 16.32, 17.05, 20.38. Reivindicacion 4: El compuesto de acuerdo con cualquiera de las reivindicaciones 1 a 3, caracterizado porque tiene un espectro infrarrojo registrado en Reflectancia Total Atenuada que tiene bandas de absorcion características a 3426, 3267, 3060, 2936, 2876, 2598, 2456, 1736, 1639, 1597, 1512, 1487, 1459, 1441, 1424, 1391, 1315, 1232, 1191, 1137, 781, 773, 735, 713, 670 cm-1. Reivindicacion 5: El compuesto de acuerdo con cualquiera de las reivindicaciones 1 a 4, caracterizado porque tiene un espectro 13C-NMR en estado solido con desplazamientos característicos (expresados en ppm con relacion a glicina (delta c = 176,03 para la resonancia C=O)) a: 177.0, 176.0, 174.7, 172.2, 169.7, 138.9, 136.4, 133.6, 131.5, 130.2, 127.8, 126.5, 125.3, 124.2, 123.2, 121.9, 55.1, 51.0, 41.9, 40.8, 38.5, 37.1, 28.4, 25.9, 23.1, 21.1 +- 0.1 ppm.
ARP100104251A 2009-12-07 2010-11-18 Acido ((3s)-3-(((1-(((2r)-2-carboxi-4-(1-naftil) butil) ciclopentil)-carbonil) amino )-2-oxo-2,3,4,5-tetrahidro-1h-1-benzazepin-1-il) acetico cristalino, su preparacion y uso AR079059A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP09178226 2009-12-07

Publications (1)

Publication Number Publication Date
AR079059A1 true AR079059A1 (es) 2011-12-21

Family

ID=41682516

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100104251A AR079059A1 (es) 2009-12-07 2010-11-18 Acido ((3s)-3-(((1-(((2r)-2-carboxi-4-(1-naftil) butil) ciclopentil)-carbonil) amino )-2-oxo-2,3,4,5-tetrahidro-1h-1-benzazepin-1-il) acetico cristalino, su preparacion y uso

Country Status (3)

Country Link
AR (1) AR079059A1 (es)
TW (1) TW201127815A (es)
WO (1) WO2011069944A1 (es)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19510566A1 (de) 1995-03-23 1996-09-26 Kali Chemie Pharma Gmbh Benzazepin-, Benzoxazepin- und Benzothiazepin-N-essigsäurederivate sowie Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
DE19638020A1 (de) 1996-09-18 1998-03-19 Solvay Pharm Gmbh Die gastrointestinale Durchblutung fördernde Arzneimittel
ATE406899T1 (de) 2004-01-12 2008-09-15 Solvay Pharm Bv Neutrale endopeptidase (nep) und humane lösliche endopeptidase (hsep) hemmer für die prophylaxe und behandlung von neurodegenerativen erkrankungen
US7232813B2 (en) 2004-01-12 2007-06-19 Solvay Pharmaceuticals B.V. Neutral endopeptidase (NEP) and human soluble endopeptidase (hSEP) inhibitors for prophylaxis and treatment of neuro-degenerative disorders
AU2005315608B2 (en) 2004-12-15 2011-03-31 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions comprising NEP-inhibitors, inhibitors of the endogenous endothelin producing system and HMG CoA reductase inhibitors

Also Published As

Publication number Publication date
TW201127815A (en) 2011-08-16
WO2011069944A1 (en) 2011-06-16

Similar Documents

Publication Publication Date Title
IL214236A0 (en) Heterocyclic compounds, pharmaceutical compositions containing them, and their use as inhibitors of the glycine transporter 1
EP2815768A3 (en) Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
IL225198A (en) Aminotetrahydropyrenic Compounds, Pharmaceutical Preparations Containing Them and Their Use in the Treatment of Diabetes
WO2006052968A3 (en) Stabilized ramipril compositions and methods of making
CL2011000867A1 (es) Formas cristalinas da, c y ii de (r)-5-[3-cloro-4-(2,3-dihidroxi-propoxi)- benz[z]ilideno]-2- ([z]- propilimino) -3-o- totil-tiazolidin-4-ona; composicion farmaceutica; y uso en el tratamiento o prevencion de rechazo de organos trasplantados, sindrome autoinmunitarios, asma, diabetes, cancer.
UA106037C2 (uk) Модулятори ampk (амф-активованої протеїнкінази)
EP2499195A4 (en) Oxygen scavengers, compositions comprising the scavengers, and artcles made from the compositions
WO2011138678A3 (en) Compositions, gels and foams with rheology modulators and uses thereof
WO2009156405A8 (en) Novel immunoadjuvant flagellin-based compounds and use thereof
WO2009155001A3 (en) Wnt protein signalling inhibitors
WO2011008823A3 (en) Peptide-mediated non-covalent delivery of active agents across the blood brain barrier
MX2011000255A (es) Combinacion de un antagonista a c-met y un compuesto aminoheteroarilo, para el tratamiento de cancer.
EA200870422A1 (ru) Улучшенное выдачное устройство
EP2186795A4 (en) (1S, 2S, 3S, 4R) -3 - [(1S) -1-ACETYLAMINO-2-ETHYL-BUTYL] -4-GUANIDINO-2-HYDROXYL-CYCLOPENTYL-1-CARBOXYLIC ACID HYDRATES AND THEIR PHARMACEUTICAL USE
WO2009115084A3 (de) Pyrrolopyrimidin-derivate und deren verwendungen
TN2012000147A1 (en) 2-oxo-1-pyrrolidinyl imidazothiadiazole derivatives
ZA200807024B (en) Alpha crystaline form of the arginine salt of perindopril, process for preparing it, and pharmaceutical compositions comprising it
IL206767A0 (en) B cell depleting antibodies, or fragments thereof, compositions comprising the same and use thereof for treating chronic fatigue syndrome
IL209304A0 (en) Peptides, peptidomimetics and derivatives thereof, the manufacturing thereof as well as their use for preparing a therapeutically and/or preventively active pharmaceutical composition
CA2634695A1 (en) Assembling a packaged bundle using an adjustable multi-shelved product transporter
NO20084942L (no) Fremgangsmate for a oke eller pavirke hyllelivet til landbruksprodukter som produserer etylen under transport og/eller lagring
GR20050100466A (el) Βελτιωμενες φαρμακευτικες συνθεσεις που περιεχουναναστολεις της αναγωγασης του 3-υδροξυ-3-μεθυλογλουταρυλοσυνενζυμου α (hmg-coa) και μεθοδος παρασκευης αυτων
AR079059A1 (es) Acido ((3s)-3-(((1-(((2r)-2-carboxi-4-(1-naftil) butil) ciclopentil)-carbonil) amino )-2-oxo-2,3,4,5-tetrahidro-1h-1-benzazepin-1-il) acetico cristalino, su preparacion y uso
NZ704023A (en) Novel rebamipide prodrug, method for producing same, and usage thereof
GB0615105D0 (en) Novel compounds

Legal Events

Date Code Title Description
FB Suspension of granting procedure